FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject	
Section 16. Form 4 or Form 5	
bligations may continue. See	

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Griffith Peter H.						2. Issuer Name and Ticker or Trading Symbol AMGEN INC [ AMGN ]									k all app Direc	licable)	g Person(s) to I		
(Last) (First) (Middle) ONE AMGEN CENTER DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 11/01/2021									belov			below)	specify	
(Street) THOUS OAKS	AND CA	A 9	91320		4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi _ine) X	-,				
(City)	(St	ate) (2	Zip)																
		Table	l - No	n-Deriva	tive S	Secui	rities	Acq	uired	l, Dis	posed of	, or E	Benefic	ially	/ Own	ed			
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day)				Execution			Date, Transaction Code (Instr.			4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			4 and Sec Ben Owi		cially   Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) c	Price	•	Transa	eported ansaction(s) astr. 3 and 4)			(111511.4)
Common Stock 11/01/2					2021				F		2,661	D	\$20	23,700(1		700(1)(2)		D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative   Conversion   Date		3. Transaction Date (Month/Day/Year)	if any	ution Date, Tra Co th/Day/Year) 8)		de (Instr. of Der Sec Acc (A) Disport of (I		osed ) r. 3, 4	6. Date Exer Expiration D (Month/Day/		ate	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Dei See (Ins	Price of rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y D	0. Ownership orm: Direct (D) or Indirect I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

## **Explanation of Responses:**

- 1. These shares include the following RSUs granted under the Company's equity plans: 12,296 RSUs which vest in one installment of 6,056 on 11/1/2022 and one installment of 6,240 on 11/1/2023; 3,384 RSUs which vest in installments of 1,116 on 5/5/2022, 1,117 on 5/5/2023 and 1,151 on 5/5/2024; and 3,338 RSUs which vest in installments of 1,101 on 4/30/2023, 1,102 on 4/30/2024 and 1,135 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- 2. These shares include 930 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.

/s/ Peter H. Griffith

11/01/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.